Analysts Set Oxford Biomedica plc (LON:OXB) Target Price at GBX 687

Oxford Biomedica plc (LON:OXB) has received an average recommendation of “Moderate Buy” from the seven analysts that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is GBX 687.

OXB has been the topic of several recent research reports. Stifel Nicolaus restated a “buy” rating and issued a GBX 950 price target on shares of Oxford Biomedica in a research report on Wednesday, March 11th. Deutsche Bank Aktiengesellschaft upped their price objective on Oxford Biomedica from GBX 735 to GBX 800 and gave the company a “buy” rating in a report on Friday, January 9th. Finally, Jefferies Financial Group started coverage on Oxford Biomedica in a report on Monday, March 23rd. They set a “buy” rating and a GBX 827 target price on the stock.

Oxford Biomedica Trading Up 0.2%

OXB opened at GBX 646 on Thursday. The firm has a 50 day simple moving average of GBX 610.51 and a 200 day simple moving average of GBX 664.27. Oxford Biomedica has a fifty-two week low of GBX 270 and a fifty-two week high of GBX 952. The company has a market cap of £781.01 million, a price-to-earnings ratio of -24.00 and a beta of 1.10. The company has a debt-to-equity ratio of 116.74, a current ratio of 2.20 and a quick ratio of 1.67.

Oxford Biomedica (LON:OXB) last announced its quarterly earnings data on Thursday, March 26th. The biopharmaceutical company reported GBX (26.92) earnings per share (EPS) for the quarter. Oxford Biomedica had a negative net margin of 17.85% and a negative return on equity of 48.56%. On average, sell-side analysts anticipate that Oxford Biomedica will post -31.0799998 earnings per share for the current year.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.